Vanguard Group Inc. Has $368.21 Million Stock Position in Guardant Health, Inc. (NASDAQ:GH)

Vanguard Group Inc. lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 3.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,052,551 shares of the company’s stock after acquiring an additional 350,606 shares during the period. Vanguard Group Inc. owned 9.75% of Guardant Health worth $368,205,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of GH. R Squared Ltd purchased a new position in Guardant Health during the 4th quarter valued at about $26,000. SBI Securities Co. Ltd. purchased a new position in Guardant Health during the 4th quarter valued at $43,000. Kimelman & Baird LLC bought a new position in shares of Guardant Health during the 4th quarter worth $58,000. Quantbot Technologies LP bought a new position in Guardant Health in the fourth quarter worth about $80,000. Finally, Jones Financial Companies Lllp grew its position in Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after purchasing an additional 817 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $43.49 on Thursday. The stock has a fifty day moving average price of $44.65 and a two-hundred day moving average price of $34.66. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89. The firm has a market cap of $5.37 billion, a P/E ratio of -12.22 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. On average, research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GH. Stifel Nicolaus lifted their price target on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Morgan Stanley lifted their target price on Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. The Goldman Sachs Group lifted their price target on shares of Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Canaccord Genuity Group increased their price target on Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Finally, Guggenheim reaffirmed a “buy” rating and set a $56.00 price target on shares of Guardant Health in a research report on Monday, February 24th. Twenty equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $48.95.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.